ORBIMED ADVISORS LLC purchased $3.6M of ETRA (indirect holdings)
ORBIMED ADVISORS LLC purchased 472,571 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at an average of $7.63 ($7.07–$7.88, $3.61M total) across 10 trades over 2026-11-03 to 2026-11-05. Filed jointly with OrbiMed Capital GP VII LLC (Director) and OrbiMed Genesis GP LLC (Director).
How this was made
The 30-second read
Why it matters
The disclosed purchase adds to OrbiMed's existing holdings, raising its ownership to over 2 million shares, indicating confidence.
Market read
Primary insider purchase filing; modest but material for a micro‑cap, may influence short‑term price.
What to watch
Potential upcoming clinical data or financing events could be the real driver.
Background
Electra Therapeutics (NASDAQ:ETRA) is a biotech focused on gene‑editing therapies. OrbiMed Advisors is a prominent healthcare investment firm.
Ticker impact
Form 4 shows OrbiMed Advisors bought $3.6M of shares, increasing its stake to 2.14M shares.
likely modest upward pressure as market prices in insider buying
Purchase size is modest for a micro‑cap but represents a significant stake increase by a director; such buys often precede short‑term price support.
Market effects
Limited; reflects micro‑cap biotech insider activity.
None
None
Counterpoint
Insider buying may be routine portfolio rebalancing, not a bullish signal.
Key entities
- companyElectra Therapeutics, Inc.
Biotech issuer of the shares purchased.
- investorOrbiMed Advisors LLC
Director and 10% owner executing the purchase.
